A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis
Latest Information Update: 23 Sep 2026
At a glance
- Drugs SAR 447754 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
Most Recent Events
- 07 Sep 2026 Planned number of patients changed from 283 to 291.
- 04 Aug 2026 Planned number of patients changed from 207 to 236.
- 16 Mar 2026 New trial record